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Abstract
Purpose Understanding the morbidity and socio-economic
implications of cancer survivorship is essential for a compre-
hensive management of oncological diseases. We compared
cancer survivors (CS) with the general population regarding
health status, use of healthcare resources and socio-economic
condition.
Methods We analyzed data from a representative sample of
the Portuguese population aged ≥15 years (n=35,229). We
defined three groups of CS, according to the time since
diagnosis and the latest cancer treatment: CS 1 diagnosis
within 12 months of interview; CS 2 diagnosis more than
12 months before and treatment in the previous 12 months;
CS 3 diagnosis and treatment more than 12 months before.
These were compared with the general population, adjusting
for differences in sex, age, and place of residence.
Results The prevalence of CS was 2.2 % (CS 1: 0.2 %; CS 2:
0.9 %, CS 3: 1.1 %). Self-perceived health status was worse
among CS and short-time incapacity more frequent among CS
1 and CS 2. Health expenses were higher in the early stages of
survivorship. Lower household income and financial difficul-
ties were more frequent in CS 1 and CS 3 men, respectively.
Conclusion This study confirmed the higher consumption of
healthcare resources and worse financial situation among CS.
Implications for Cancer Survivors Our study provides valu-
able information for understanding the global impact of cancer
survivorship.
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Introduction
An increasing number of cancer patients has been observed in
the last decades, especially due to population growth, aging
and screening [1–5]; in 2012, over six million new cases were
estimated to have occurred in the more developed regions [6].
Concurrently, early diagnosis and effective treatment resulted
in improved survival [7]; the 5-year relative survival for all
cancers was 52.0 % among cases diagnosed in Europe be-
tween 1995 and 1999 [8], and 68.1 % in the USA in 2003–
2009 [9]. In Portugal, almost 50,000 new cancers are diag-
nosed each year [6]; among patients diagnosed in the North
during 2005–2006, the 5-year relative survival was above
60 % [10].
The morbidity and socio-economic effects of cancer
diagnosis and treatment are important components of its
overall burden among the growing population of living
persons ever diagnosed with cancer [11, 12]. Cancer sur-
vivors often suffer from persistent symptoms (pain, dis-
tress, fatigue or cognitive impairment), as well as employ-
ment changes and financial difficulties, that could affect
not only the patient but also their whole families, among
other short and long term effects [13, 11]. Assessing the
impact of these phenomena in different settings is needed
to support a more comprehensive management of onco-
logical diseases.
Therefore, we aimed to assess the impact of cancer survi-
vorship on health status, use of healthcare and socio-economic
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condition, using data from the latest Portuguese National
Health Survey.
Methods
The present analysis is based on data collected as part of the
fourth National Health Survey (IV-NHS), which is a nation-
wide community-based cross-sectional study [14].
Population sampling and data collection
A sample of households was defined, using data from the
2001 Population and Housing Census, to be used as the
sampling frame for household surveys conducted by the Na-
tional Institute of Statistics (INE). It included 1,408 geograph-
ical units with at least 240 households each, selected system-
atically within larger geographical strata, with a probability
proportional to the number of households in each unit. A
random sample of the households was then selected and all
dwellers were eligible.
During a total of 52 weeks, between February 2005 and
January 2006, 41,193 persons from 15,239 households were
evaluated. All the information was collected directly from the
individuals or from proxies, through computer-assisted inter-
views performed by trained interviewers.
The participants that reported a previous cancer diagnosis
(medically confirmed) were considered cancer survivors (CS)
and were further divided in three groups: (a) those with the
diagnosis in the previous 12 months (CS 1); (b) those with a
diagnosis more than 12 months before the interview, but
having been submitted to a cancer treatment in the previous
12 months (CS 2); (c) those with cancer diagnosis and treat-
ment more than 12 months before (CS 3).
A detailed description of the assessment of the participants’
health status, healthcare consumption, and socio-economic
characteristics is presented in footnotes in the tables and
figures depicting the results.
Statistical analysis
Data analysis was restricted to participants aged ≥15 years,
corresponding to a sample of 35,229 respondents. The
evaluation of the use of preventive care procedures and
the financial status of the respondents was accomplished
only in subsamples of approximately one quarter of the
total sample, evaluated in weeks of data collection 27 to
39 and 40 to 52, respectively. Data on the general health
status and quality of life domains of the questionnaire
were collected only from non-proxy respondents (approx-
imately two thirds of the sample). All analyses were
conducted with STATA®, version 11.1 (StataCorp LP,
College Station, TX, USA), using sampling weights,
calculated based on the inverse of the probability of
selection of each sampling unit, further corrected for
nonresponses and for the effective number of subjects
evaluated, regarding the age and sex structures.
We computed weighted prevalences and corresponding
95 % confidence intervals (95%CI), as well as age-, region-,
and education-adjusted prevalence ratios (PR), using Poisson
regression [15] to compare each group of CS, namely CS 1,
CS 2, and CS 3, with the participants not reporting a previous
diagnosis of cancer (NC). To analyze data on family income
we assigned to each category the corresponding midpoint and
treated the variable as continuous; data were described with
box-and-whisker plots and different groups were compared
using multivariable linear regression.
Results
A total of 784 participants were cancer survivors, correspond-
ing to a weighted prevalence of 2.2 % (95%CI: 1.9–2.4), from
which 71 (0.2%, 95%CI: 0.1–0.2) reported a cancer diagnosis
in the last 12 months (CS 1), 321 (0.9 %, 95%CI: 0.7–1.1)
were diagnosed a cancer more than 12 months before, but had
been treated during the preceding 12 months (CS 2), and 392
(1.1 %, 95%CI: 0.9–1.3) had been diagnosed and treated for
cancer more than 12 months before (CS 3).
The percentage of men was lowest in CS 3 (28.9 %) and
ranged between 48.0 % and 57.4 % in NC and CS 1, respec-
tively. CS were more frequently aged above 65 years (per-
centage ranging from 52.7 % of CS 1 to 43.7 % of CS 3) than
NC (19.7 %). Less educated participants were more prevalent
among CS (Table 1).
Participants’ health status and healthcare consumption
Compared to NC, CS reported an approximately 30 % higher
prevalence of bad perceived health status, regardless of the
time since the diagnosis, while significantly higher levels of
short-term incapacity were observed only in CS 1 (PR=3.7)
and CS 2 (PR=2.0) (Fig. 1). CS had a 20 % higher prevalence
of medication consumption, though the PR for medical con-
sultations decreased from 1.5 in CS 1 to 1.2 in CS 3 (Fig. 1).
Regarding preventive care, CS reported an approximately
20 % higher prevalence of cholesterol evaluation, and smaller
differences were observed for blood pressure assessment,
which was significantly more frequent only in CS 1 and CS
2 (PR=1.1). All groups reported a low frequency of flu
vaccination, though a non-significantly 20 % higher preva-
lence was observed among CS 2 and CS 3 (Fig. 1). The results
were similar when data were analyzed separately for men
and women (data not shown).
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Among women, mammography use was more frequent in
cancer survivors, being especially higher in the CS 1 group
(PR=4.3). The use of cervical cytology was more frequent
only in CS 1 (PR=5.3) (Fig. 1).
Table 1 Socio-demographic characteristics of cancer survivors and non-cancer individuals
NC Cancer survivor
CS 1 CS 2 CS 3
% (95%CI)a % (95%CI)a % (95%CI)a % (95%CI)a
Gender
Female 52.0 (51.0–53.0) 42.6 (20.2–65.0) 47.1 (36.7–57.5) 71.1 (63.5–78.8)
Male 48.0 (47.0–49.0) 57.4 (35.0–79.8) 52.9 (42.5–63.2) 28.9 (21.2–36.5)
Age (years)
15–34 33.8 (32.7–34.8) 4.3 (0.0–11.0) 2.1 (0.0–4.6) 12.6 (5.4–19.8)
35–64 46.6 (45.6–47.6) 42.9 (19.4–66.5) 50.2 (39.8–60.7) 43.7 (35.2–52.2)
≥65 19.7 (18.9–20.4) 52.7 (29.2–76.2) 47.6 (37.2–58.0) 43.7 (35.4–52.0)
Education (years)
None 11.8 (11.1–12.4) 21.3 (4.7–37.9) 21.3 (13.1–29.4) 18.4 (12.1–24.7)
1–4 31.6 (30.7–32.5) 51.3 (28.0–74.6) 56.2 (46.0–66.5) 43.6 (35.1–52.1)
5–6 14.9 (14.1–15.7) 14.9 (0.0–33.6) 5.5 (1.2–9.8) 13.1 (6.9–19.3)
7–9 14.7 (14.0–15.5) 5.3 (0.0–10.7) 7.1 (1.9–12.3) 10.3 (4.6–16.0)
10–12 14.7 (14.0–15.4) 5.4 (0.0–10.8) 6.1 (0.7–11.5) 7.3 (3.7–10.8)
>12 12.3 (11.6–13.0) 1.9 (0.0–4.5) 3.8 (0.0–7.9) 7.3 (3.0–11.6)
NC Participants not reporting a previous diagnosis of cancer, CS 1 Cancer survivors with a cancer diagnosis in the previous 12 months, CS 2 Cancer
survivors with a cancer diagnosis with more than 12months, but have been submitted to treatment in the 12months before,CS 3Cancer survivors with a
cancer diagnosis or treatment with more than 12 months
aWeighted prevalence
Fig. 1 Participant’s health status and healthcare consumption, in non-
cancer participants and cancer survivors. (a) Age-, region-, and educa-
tion-adjusted prevalence ratio and corresponding 95 % confidence inter-
val: PR (95%CI). (b) Poisson regression model also included a variable
on the history of hypertension. (c) Perceived health status was evaluated
with a question asking how the participants classify their health status.
They could answer: “very good”, “good”, “reasonable”, “bad” and “very
bad”. For further analysis the answers were aggregated within “good”
(the first three options) and “bad” categories (the last two options). (d)
Incapacity was evaluated with the question: “During the last 2 weeks,
how many days did you have your ability to accomplish regular activities
compromised due to disease, accident, violence or other health prob-
lem?”; those respondents that reported at least 1 day were considered to
have incapacity. (e) Participants were asked about the number of medical
consultations in the previous 3 months. (f) Participants were asked about
the consumption of any medicines in the past 2 weeks. (g) Participants
were asked about the use of preventive care measures during the previous
year: flu vaccination, blood pressure measurement and cholesterol eval-
uation. (h) Mammography and cervical cytology were evaluated by
asking the participants if they had been submitted to the procedure in
the previous 12 months, and it was restricted to women evaluated during
the weeks 27 to 39. NC Participants not reporting a previous diagnosis of
cancer. CS 1 Cancer survivors with a cancer diagnosis in the previous
12months.CS 2Cancer survivors with a cancer diagnosis with more than
12months, but have been submitted to treatment in the 12months before.
CS 3 Cancer survivors with a cancer diagnosis or treatment with more
than 12 months
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Socio-economic implications
A higher proportion of CS reported health expenditures in the
last 2 weeks, especially in the CS 1 group (PR=1.4), though
differences were not statistically significant. The level of
health expenditures was nearly twice higher among CS 1 than
in NC; smaller and non-statistically significant differences
were observed between CS 2 or CS 3 and NC (Fig. 2). Results
were similar when gender stratified analyses were conducted
(data not shown).
The household income was lower among male cancer
survivors, mainly in the CS 1 group (β=−304.3; −431.3,
−117.3), but no significant differences were observed among
women (Fig. 3).
We found a higher prevalence of financial difficulties
among cancer survivors, only among men, which was statis-
tically significant in the CS 3 group (PR=2.2) (Fig. 4).
Discussion
The prevalence of CS in the Portuguese adult population was
2.2 % in 2005/2006. CS reported worse health status and a
higher consumption of healthcare resources, both for men and
women, whereas financial consequences were more frequent
in male CS.
The recent estimates of cancer prevalence in the USA
(2007) [16] and in the UK (2008) [17], based on data from
cancer registries, were 3.9 % and 3.3 %, respectively. The
lower prevalence observed in our study may reflect the lower
crude incidence rates in the Portuguese setting (405.4/100,000
vs. 461.1/100,000 in the USA and 496.9/100,000 in the UK)
[18], as well as worse survival among Portuguese cancer
patients in comparison with those in the USA and similar to
those observed in the UK [7]. On other hand, the present study
assessed the prevalence of CS using cross-sectional self-
reported data, which may contribute to an overestimation of
cancer survivorship due to misclassification of diagnoses of
benign conditions as cancer [19].
According to our results the estimated number of CS in
Portugal would be approximately 220,000, whom may be
expected to suffer several physical and psychological adverse
effects of diagnosis and treatment [12, 11]. Our results high-
light a worse perceived health status among cancer survivors,
independently of the survivorship period, in accordance with
previous observations in other settings, probably reflecting
high levels of bothering symptoms, such as persistent pain,
fatigue, distress and cognitive impairment [13, 20, 21].
The first 12 months after the diagnosis are often associated
with a high symptom burden, especially as a consequence of
treatment, which frequently impairs the ability to maintain the
regular activities [13]. In accordance, we found the highest
prevalence of short-term incapacity among the CS diagnosed
more recently.
Despite some heterogeneity across different studies from
several countries, cancer survivors often have a greater utili-
zation of healthcare services, which mainly correspond to
consultations with the primary care physician and/or the on-
cologist [22]. The frequency of those contacts with the
healthcare system is higher in the first year, mostly related to
diagnosis and treatment, and tends to decrease to nearly half
during the three subsequent years [22, 23]. Similarly, in our
study CS reported a higher frequency of medical consultations
during the first 12 months. However, they maintained a pat-
tern of high consumption of medicines for a longer period,
possibly reflecting the bothering symptoms and chronic con-
ditions that persist after cancer diagnosis and primary
treatment.
Preventive care assumes an important role among cancer
survivors, due to their poorer health condition, which is com-
monly associated with a higher prevalence of comorbidities
and an increased risk of second primary tumors [12, 24, 25].
Several studies comparing the use of preventive care between
CS and the general population yielded inconsistent results [26,
23, 27–30], which may reflect the fact that these studies were
performed in different settings, with heterogeneous models of
health financing and accessibility to healthcare services.
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Fig. 2 Health-related expenditures by household members in the previ-
ous 2 weeks, in non-cancer participants and cancer survivors. (a) Age-,
region-, and education-adjusted prevalence ratio and corresponding 95 %
confidence interval: PR (95%CI). (b) Participants were asked about the
health-related expenditures by household members in the previous
2 weeks (including medical consultations, medications, diagnostic pro-
cedures and other treatments). (c) Median (30 €) of the level of expenses,
among those that reported health-related expenditures. NC Participants
not reporting a previous diagnosis of cancer.CS 1Cancer survivors with a
cancer diagnosis in the previous 12months. CS 2 Cancer survivors with a
cancer diagnosis with more than 12 months, but have been submitted to
treatment in the 12 months before. CS 3 Cancer survivors with a cancer
diagnosis or treatment with more than 12 months
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Moreover, there were also differences regarding age and tumor
topography distributions, as well as several lengths of time
since the diagnosis, which are important determinants of pre-
ventive care use [30]. In our study, CS reported a higher
frequency of blood pressure and cholesterol evaluations, as
well as cancer screening (cervical cytology and mammogra-
phy) among subjects with a more recent cancer diagnosis;
however, the latter may reflect, at least partially, the misclassi-
fication of diagnosis mammography exams as screening.
Regarding flu vaccination, we should emphasize the lower
proportion of CS undergoing immunization as a public health
concern, namely in comparison with observations from other
settings [11]. This is especially relevant in our sample since
we had more than 20 % of the individuals with age above
65 years and a large percentage of the CS were probably under
immunosuppressant treatments, which are some of the
established criteria to perform the immunization [31].
Several studies have illustrated the financial impact that
comes with the variety of problems posed by a cancer diag-
nosis [32]. Although in Portugal the payment of cancer treat-
ments is mostly supported by the National Health System,
there are studies performed in other settings, mainly in the
USA, showing that even for insured patients the cost of cancer
diagnosis and treatment can represent a barrier to high-quality
care [33]. Out-of-pocket expenses associated with cancer
treatment may still be substantial and lead to delay in treat-
ment, noncompliance, exhaustion of savings and personal
bankruptcy [34]. In our sample, we found a higher level of
health expenditures among cancer survivors, mostly in the
first stages of survivorship.
CS also reported lower levels of family income after the
cancer diagnosis, which were particularly relevant among
male survivors. This decrease is in accordance with the known
changes in the working situation among cancer patients, such
as unemployment due to incapacity, switch to part-time activ-
ities and early-retirement [35]. The high level of health ex-
penditures among CS, concurrently with these lower levels of
family income in men, may explain the higher frequency of
financial difficulties that we found in male CS, mostly among
those surviving for longer periods.
The follow-up of the growing population of CS, which
reveals a higher consumption of healthcare resources, may
need to be reassigned to primary care services with well-
established standard protocols of clinical surveillance, in order
to decentralize services and facilitate the access of these
individuals to healthcare. Policy makers might also have to
consider setting up effective supportive programs to help the
most socially disadvantaged CS, with the perspective of min-
imizing the financial difficulties and their negative impact in
the quality of life and in the disease survival [36], namely
through multidisciplinary interventions to enhance return-to-
work for CS [37].
Despite the strengths of using a large nationally represen-
tative sample with data from the latest Portuguese National
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Health Survey, constituting an important piece of information
for understanding the dimension of this problem in Portugal,
the present study has some limitations. CS were identified by
self-report, and data about stage at diagnosis, treatment, re-
currence, or other clinical characteristics were not available.
The accuracy of information on a previous cancer diagnosis
was improved by considering only those reported to be med-
ically confirmed, but the lack of additional information on
these events precluded a finer assessment of the burden of
cancer survivorship in Portugal. Data on some variables was
available only for subsamples of the participants in the nation-
al Health Survey, which compromised the statistical power of
the study, but this is not expected to compromise the validity
of the conclusions. Also, for some variables proxy respon-
dents were allowed, whichmay contribute to information bias;
however, we conducted sensitivity analyses excluding data
obtained from proxies and the conclusions remained essen-
tially the same (data not shown). Although we excluded from
our analyses the participants aged <15 years, because only 6
CS were observed in this age group, the small proportion of
subjects aged 15–34 years among CS 1 and CS 2 could have
contributed for spurious age-adjusted estimates; however, a
sensitivity analysis including only the participants aged
≥35 years yielded essentially the same results (data not
shown). The establishment of causal relationships between
the onset of comorbid conditions and the cancer diagnosis or
treatment is limited by the cross-sectional design of the study,
which also leads to an underrepresentation of newly diag-
nosed cancers and those with a short survival. Nevertheless,
to our knowledge, this is the first study addressing this topic in
a representative sample of the Portuguese population and
provides valuable information for understanding a different
dimension of the burden of cancer survivorship, in addition to
increasing the awareness to this growing public health con-
cern, which brings new challenges to healthcare provision and
social security.
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